Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

With a focus on novel cell therapies for cancer, Chimeric currently has three novel cell therapies in four clinical 1 trials. Each has advanced to human trials. Our first asset, CHM CDH17, is in …

Chimeric's diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies.

Chimeric Therapeutics is focused upon delivering results for patients, partners and investors.

Chimeric Therapeutics is led by a team of cell therapy pioneers and experts who are committed to bringing the promise of cell therapy to life for more patients with cancer.

Chimeric Therapeutics is focused upon delivering results for patients, partners and investors.

The CORE-NK platform is a transformative platform technology for Chimeric enabling the accelerated development of multiple next generation, off the shelf NK and CAR-NK products. …

Patient, parter or investor, we're here to answer anything you need to know. First name *. Last name *

View share price, top shareholders, your shareholding, and interact with announcements for Chimeric Therapeutics Limited.